|
| | SB0194 Enrolled | | LRB102 04364 SPS 14382 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Pharmacy Practice Act is amended by |
5 | | changing Section 4 as follows:
|
6 | | (225 ILCS 85/4) (from Ch. 111, par. 4124)
|
7 | | (Section scheduled to be repealed on January 1, 2023)
|
8 | | Sec. 4. Exemptions. Nothing contained in any Section of |
9 | | this Act shall
apply
to, or in any manner interfere with:
|
10 | | (a) the lawful practice of any physician licensed to |
11 | | practice medicine in
all of its branches, dentist, |
12 | | podiatric physician,
veterinarian, or therapeutically or |
13 | | diagnostically certified optometrist within
the limits of
|
14 | | his or her license, or prevent him or her from
supplying to |
15 | | his
or her
bona fide patients
such drugs, medicines, or |
16 | | poisons as may seem to him appropriate;
|
17 | | (b) the sale of compressed gases;
|
18 | | (c) the sale of patent or proprietary medicines and |
19 | | household remedies
when sold in original and unbroken |
20 | | packages only, if such patent or
proprietary medicines and |
21 | | household remedies be properly and adequately
labeled as |
22 | | to content and usage and generally considered and accepted
|
23 | | as harmless and nonpoisonous when used according to the |
|
| | SB0194 Enrolled | - 2 - | LRB102 04364 SPS 14382 b |
|
|
1 | | directions
on the label, and also do not contain opium or |
2 | | coca leaves, or any
compound, salt or derivative thereof, |
3 | | or any drug which, according
to the latest editions of the |
4 | | following authoritative pharmaceutical
treatises and |
5 | | standards, namely, The United States |
6 | | Pharmacopoeia/National
Formulary (USP/NF), the United |
7 | | States Dispensatory, and the Accepted
Dental Remedies of |
8 | | the Council of Dental Therapeutics of the American
Dental |
9 | | Association or any or either of them, in use on the |
10 | | effective
date of this Act, or according to the existing |
11 | | provisions of the Federal
Food, Drug, and Cosmetic Act and |
12 | | Regulations of the Department of Health
and Human |
13 | | Services, Food and Drug Administration, promulgated |
14 | | thereunder
now in effect, is designated, described or |
15 | | considered as a narcotic,
hypnotic, habit forming, |
16 | | dangerous, or poisonous drug;
|
17 | | (d) the sale of poultry and livestock remedies in |
18 | | original and unbroken
packages only, labeled for poultry |
19 | | and livestock medication;
|
20 | | (e) the sale of poisonous substances or mixture of |
21 | | poisonous substances,
in unbroken packages, for |
22 | | nonmedicinal use in the arts or industries
or for |
23 | | insecticide purposes; provided, they are properly and |
24 | | adequately
labeled as to content and such nonmedicinal |
25 | | usage, in conformity
with the provisions of all applicable |
26 | | federal, state and local laws
and regulations promulgated |
|
| | SB0194 Enrolled | - 3 - | LRB102 04364 SPS 14382 b |
|
|
1 | | thereunder now in effect relating thereto
and governing |
2 | | the same, and those which are required under such |
3 | | applicable
laws and regulations to be labeled with the |
4 | | word "Poison", are also labeled
with the word "Poison" |
5 | | printed
thereon in prominent type and the name of a |
6 | | readily obtainable antidote
with directions for its |
7 | | administration;
|
8 | | (f) the delegation of limited prescriptive authority |
9 | | by a physician
licensed to
practice medicine in all its |
10 | | branches to a physician assistant
under Section 7.5 of the |
11 | | Physician Assistant Practice Act of 1987. This
delegated |
12 | | authority under Section 7.5 of the Physician Assistant |
13 | | Practice Act of 1987 may, but is not required to, include |
14 | | prescription of
controlled substances, as defined in |
15 | | Article II of the
Illinois Controlled Substances Act, in |
16 | | accordance with a written supervision agreement;
|
17 | | (g) the delegation of prescriptive authority by a |
18 | | physician
licensed to practice medicine in all its |
19 | | branches or a licensed podiatric physician to an advanced |
20 | | practice
registered nurse in accordance with a written |
21 | | collaborative
agreement under Sections 65-35 and 65-40 of |
22 | | the Nurse Practice Act; and
|
23 | | (h) the sale or distribution of dialysate or devices |
24 | | necessary to perform home peritoneal renal dialysis for |
25 | | patients with end-stage renal disease, provided that all |
26 | | of the following conditions are met: |
|
| | SB0194 Enrolled | - 4 - | LRB102 04364 SPS 14382 b |
|
|
1 | | (1) the dialysate, comprised of dextrose or |
2 | | icodextrin, or devices are approved or cleared by the |
3 | | federal Food and Drug Administration, as required by |
4 | | federal law; |
5 | | (2) the dialysate or devices are lawfully held by |
6 | | a manufacturer or the manufacturer's agent, which is |
7 | | properly registered with the Board as a manufacturer, |
8 | | third-party logistics provider, or wholesaler; |
9 | | (3) the dialysate or devices are held and |
10 | | delivered to the manufacturer or the manufacturer's |
11 | | agent in the original, sealed packaging from the |
12 | | manufacturing facility; |
13 | | (4) the dialysate or devices are delivered only |
14 | | upon receipt of a physician's prescription by a |
15 | | licensed pharmacy in which the prescription is |
16 | | processed in accordance with provisions set forth in |
17 | | this Act, and the transmittal of an order from the |
18 | | licensed pharmacy to the manufacturer or the |
19 | | manufacturer's agent; and |
20 | | (5) the manufacturer or the manufacturer's agent |
21 | | delivers the dialysate or devices directly to: (i) a |
22 | | patient with end-stage renal disease, or his or her |
23 | | designee, for the patient's self-administration of the |
24 | | dialysis therapy or (ii) a health care provider or |
25 | | institution for administration or delivery of the |
26 | | dialysis therapy to a patient with end-stage renal |
|
| | SB0194 Enrolled | - 5 - | LRB102 04364 SPS 14382 b |
|
|
1 | | disease. |
2 | | This paragraph (h) does not include any other drugs |
3 | | for peritoneal dialysis, except dialysate, as described in |
4 | | item (1) of this paragraph (h). All records of sales and |
5 | | distribution of dialysate to patients made pursuant to |
6 | | this paragraph (h) must be retained in accordance with |
7 | | Section 18 of this Act. A student pharmacist or licensed |
8 | | pharmacy technician engaged in remote prescription |
9 | | processing under Section 25.10 of this Act at a licensed |
10 | | pharmacy described in item (4) of this paragraph (h) shall |
11 | | be permitted to access an employer pharmacy's database |
12 | | from his or her home or other remote location while under |
13 | | the supervision of a pharmacist for the purpose of |
14 | | performing certain prescription processing functions, |
15 | | provided that the pharmacy establishes controls to protect |
16 | | the privacy and security of confidential records. |
17 | | (Source: P.A. 100-218, eff. 8-18-17; 100-513, eff. 1-1-18; |
18 | | 100-863, eff. 8-14-18; 101-420, eff. 8-16-19 .)
|
19 | | Section 99. Effective date. This Act takes effect upon |
20 | | becoming law. |